Proliferative effects of estradiol- or ethinylestradiol-progestogen combinations on human breast cancer cells in an intermitted and a long-term regimen

Hormone and Metabolic Research

Volumn 44, Issue 6, 2012, Pages 415-421

  Merki Feld, G S ^a   Seeger, H ^b   Mueck, A O ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

breast cancer cells; continuous incubation; estradiol; ethinylestradiol; intermitted incubation; progestogens; proliferation

Indexed keywords

DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETONOGESTREL; GESTAGEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; HUMANS; PROGESTINS; TIME FACTORS;

EID: 84861715649     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1308999     Document Type: Article

References (35)

1. Althuis M D, Brogan D R, Coates R J, Daling J R, Gammon M D, Malone K E, Schoenberg J B, Brinton L A. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer: 2003; 88 50 57 (Pubitemid 36241218)
2. Brinton L A, Gammon M D, Malone K E, Schoenberg J B, Daling J R, Coates R J. Modification of oral contraceptive relationships on breast cancer risk by selected factors among younger women. Contraception: 1997; 55 197 203 (Pubitemid 27435164)
3. Holmberg L, Lund E, Bergstrom R, Adami H O, Meirik O. Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer: 1994; 30A 351 354 (Pubitemid 24152477)
4. Newcomb P A, Longnecker M P, Storer B E, Mittendorf R, Baron J, Clapp R W, Trentham-Dietz A, Willett W C. Recent oral contraceptive use and risk of breast cancer (United States). Cancer Causes Control: 1996; 7 525 532 (Pubitemid 26306785)
5. Reeves G K, Patterson J, Vessey M P, Yeates D, Jones L. Hormonal and other factors in relation to survival among breast cancer patients. Int J Cancer: 2000; 89 293 299 (Pubitemid 30430747)
6. Trivers K F, Gammon M D, Abrahamson P E, Lund M J, Flagg E W, Moorman P G, Kaufman J S, Cai J, Porter P L, Brinton L A, Eley J W, Coates R J. Oral contraceptives and survival in breast cancer patients aged 20 to 54 years. Cancer Epidemiol Biomarkers Prev: 2007; 16 1822 1827 (Pubitemid 47450512)
7. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet: 1996; 347 1713 1727
8. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception: 2010; 82 221 229
9. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med: 2001; 344 276 285 (Pubitemid 32108534)
10. Press D J, Sullivan-Halley J, Ursin G, Deapen D, McDonald J A, Strom B L, Norman S A, Simon M S, Marchbanks P A, Folger S G, Liff J M, Burkman R T, Malone K E, Weiss L K, Spirtas R, Bernstein L. Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women's contraceptive and reproductive experiences study. Am J Epidemiol: 2011; 173 38 47
11. Chlebowski R T, Anderson G L, Gass M, Lane D S, Aragaki A K, Kuller L H, Manson J E, Stefanick M L, Ockene J, Sarto G E, Johnson K C, Wactawski-Wende J, Ravdin P M, Schenken R, Hendrix S L, Rajkovic A, Rohan T E, Yasmeen S, Prentice R L. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA: 2010; 304 1684 1692
12. Africander D, Verhoog N, Hapgood J P. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids: 2011; 76 636 652
13. Zhu Y, Hanna R N, Schaaf M J, Spaink H P, Thomas P. Candidates for membrane progestin receptors - past approaches and future challenges. Comp Biochem Physiol C Toxicol Pharmacol: 2008; 148 381 389
14. Heikinheimo O. Long-cycle combined contraception: less bleeding and increased subject satisfaction. Acta Obstet Gynecol Scand: 2006; 85 517 518 (Pubitemid 43995064)
15. Wiegratz I, Hommel H H, Zimmermann T, Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception: 2004; 69 37 42 (Pubitemid 38076964)
16. Merki-Feld G S, Seeger H, Mueck A O. Comparison of the proliferative effects of ethinylestradiol on human breast cancer cells in an intermittent and a continuous dosing regime. Horm Metab Res: 2008; 40 206 209 (Pubitemid 351690525)
17. Lippert C, Seeger H, Wallwiener D, Mueck A O. Comparison of the effects of 17alpha-ethinylestradiol and 17beta-estradiol on the proliferation of human breast cancer cells and human umbilical vein endothelial cells. Clin Exp Obstet Gynecol: 2002; 29 87 90 (Pubitemid 34815247)
18. Gompel A, Somaï S, Chaouat M, Kazem A, Kloosterboer H J, Beusman I, Forgez P, Mimoun M, Rostène W. Hormonal regulation of apoptosis in breast cells and tissues. Steroids: 2000; 65 593 598
19. Frasor J, Danes J M, Komm B, Chang K C, Lyttle C R, Katzenellenbogen B S. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology: 2003; 144 4562 4574 (Pubitemid 37204856)
20. Dai J, Jian J, Bosland M, Frenkel K, Bernhardt G, Huang X. Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status. Breast: 2008; 17 172 179 (Pubitemid 351467953)
21. Chen F P, Chien M H, Chen H Y, Ng Y T. Effects of different progestogens on human breast tumor cell growth. Climacteric: 2011; 14 345 351
22. Hofseth L J, Raafat A M, Osuch J R, Pathak D R, Slomski C A, Haslam S Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab: 1999; 84 4559 4565
23. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J: 1996; 15 1292 1300
24. Ballaré C, Vallejo G, Vicent G P, Saragüeta P, Beato M. Progesterone signaling in breast and endometrium. J Steroid Biochem Mol Biol: 2006; 102 2 10 (Pubitemid 44750650)
25. Lee K L, Dai Q, Hansen E L, Saner C N, Price T M. Modulation of ATP-induced calcium signaling by progesterone in T47D-Y breast cancer cells. Mol Cell Endocrinol: 2010; 319 109 115
26. Sawan C, Herceg Z. Histone modifications and cancer. Adv Genet: 2010; 70 57 85
27. Thomas D B, Noonan E A. WHO Collaborative Study of Neoplasia and Steroid Contraceptive Breast cancer and specific types of combined oral contraceptives. Br J Cancer: 1992; 65 108 113
28. UK National Case-Control Study Group Oral contraceptives and cancer risk in young women. Lancet: 1989; 1 973 982
29. Vessey M P, Mc Pherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer: 1989; 59 613 617 (Pubitemid 19111756)
30. Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: A large Norwegian cohort study. In J Cancer: 2003; 105 844 850 (Pubitemid 36706110)
31. Hunter D J, Colditz G A, Hankinson S E, Malspeis S, Spiegelman D, Chen W, Stampfer M J, Willett W C. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev: 2010; 19 2496 2502
32. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception: 2000; 62 29 38
33. Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contraception Reprod Health Care: 2009; 14 221 232
34. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA: 2002; 288 321 333
35. Neubauer H, Yang Y, Seeger H, Fehm T, Cahill M A, Tong X, Ruan X, Mueck A O. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause: 2011; 18 845 850